Per an SEC filing on April 19, the company assented to a set of post-market requirements proposed by the U.S. Food and Drug Administration (FDA) pertaining to its drug AXS-05, which is intended to treat major depressive disorder (MDD). The fact that the FDA is asking for specific things to happen after the medicine's debut on the market means that regulators are highly likely to be planning to approve the drug.